Taiwan’s PharmaEssentia gains US recognition for rare blood disorder drug
National Comprehensive Cancer Network adds Ropeg to guidelines after Phase 3 trial shows 43% long-term patient response
Jan. 26, 2026 13:46
National Comprehensive Cancer Network adds Ropeg to guidelines after Phase 3 trial shows 43% long-term patient response